comunicacio

Researchers identify new genes predisposing to colorectal polyposis

A group from IDIBELL, the Catalan Institute of Oncology and CIBERONC has identified new genes predisposing to different types of polyposis which, if confirmed, could determine the clinical management of carriers.

Researchers identify new genes predisposing to colorectal polyposis Read More »

The Generalitat recognizes 32 IDIBELL groups as Consolidated or Emerging Research Groups

The Agency for the Management of University and Research Grants (AGAUR) has published this week the final resolution of the call for grants to support the activities of research groups from universities, centers and foundations. In this year’s call, 32 IDIBELL groups have been recognized as Consolidated or Emerging Research Groups, of which 19 will receive funding.

The Generalitat recognizes 32 IDIBELL groups as Consolidated or Emerging Research Groups Read More »

Researchers generate a stem cell-based model to study an ultra-rare disease that causes childhood parkinsonism

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), the Sant Joan de Déu Research Institute (IRSJD), Sant Pau Research Institute (IIB Sant Pau) and the UB generated the first model of this disease that reproduce patients’ characteristics and response to treatment.

Researchers generate a stem cell-based model to study an ultra-rare disease that causes childhood parkinsonism Read More »

A bioinformatics program will accelerate the diagnosis of hereditary cancer

Bioinformaticians from the Bellvitge Biomedical Research Institute (IDIBELL) and geneticists from the Molecular Diagnostic Laboratory of the Catalan Institute of Oncology (ICO) joined forces to develop a program that facilitates genetic variants classification, as it collects and combines the available information to offer a first classification of the variants.

A bioinformatics program will accelerate the diagnosis of hereditary cancer Read More »

Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients

It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.

Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients Read More »

Bellvitge Hospital and IDIBELL successfully test a new method to compare two multiple sclerosis treatments

The study compares the use of two drugs through what they have called a natural experiment, which opens the doors to a new research methodology to compare highly effective treatments, minimizing possible biases in the analysis of the different groups.

Bellvitge Hospital and IDIBELL successfully test a new method to compare two multiple sclerosis treatments Read More »

Scroll to Top